Insulet Corporation, the pioneering leader in tubeless insulin pump technology with its renowned Omnipod brand, has announced a significant leadership transition. Ashley McEvoy has been appointed President and Chief Executive Officer, effective April 28, 2025, succeeding Jim Hollingshead, who has stepped down from his roles as CEO and Board member. This change comes at a pivotal time as Insulet projects exceeding its first-quarter 2025 revenue guidance and raising its full-year 2025 revenue outlook, signaling robust growth momentum.
Ashley McEvoy brings nearly 30 years of distinguished healthcare leadership experience, notably from her extensive tenure at Johnson & Johnson, where she served as Executive Vice President and Worldwide Chairman of its MedTech business. Under her leadership, Johnson & Johnson’s MedTech division, with over 60,000 employees and $30 billion in revenue, saw accelerated growth and an expanded product pipeline. McEvoy’s deep expertise in diabetes care positions her uniquely to steer Insulet’s mission forward.
The Board of Directors’ decision for this leadership change underscores a strategic move to advance innovation and global expansion. Jim Hollingshead’s tenure saw the successful launch of the Omnipod 5 Automated Insulin Delivery system, which dominates the US and European type 1 diabetes markets and led the way in automated insulin delivery for type 2 diabetes in the US. This product innovation has established Insulet as a clear leader in diabetes care technology.
Financially, Insulet reported fiscal year 2024 revenues of approximately $2.07 billion, reflecting a healthy year-over-year revenue growth rate of 22.1%. The company now expects to surpass its previously issued first-quarter guidance and increase its full-year 2025 revenue projections, emphasizing sustained operational success amid evolving market dynamics.
The leadership change took effect immediately on April 28, 2025, according to the company’s 8-K filing with the SEC. Insulet is headquartered in Acton, Massachusetts, and competes in the global MedTech space targeting diabetes management solutions.
This leadership transition is critical amidst a highly competitive and rapidly evolving MedTech landscape. McEvoy’s appointment signals a commitment to scaling Insulet’s innovative Omnipod platform further, expanding global market reach, and enhancing shareholder value. Notably, the company postponed its planned Investor Day (originally scheduled for June 5, 2025) to align with this transition, with a rescheduled date forthcoming.
Insulet’s guidance raise and robust 2024 financial performance indicate positive forward momentum. The Omnipod platform’s innovative design delivers up to three days of continuous insulin delivery without needles, which has revolutionized diabetes care for hundreds of thousands globally. Under McEvoy’s leadership, projected enhancements in product innovation and global expansion are expected to drive significant top-line growth and operational leverage.
Previous earnings calls highlighted Insulet’s focus on expanding pharmacy channel access, manufacturing capabilities, and customer loyalty—key pillars McEvoy identified as strengths to capitalize on. The emphasis on innovation and growth aligns with Insulet’s historical strategy to redefine diabetes care through the Omnipod system.
Insulet Corporation is entering a transformative phase with Ashley McEvoy’s leadership. With a solid foundation laid by her predecessor and a strong financial footing demonstrated by over $2 billion in revenue and 22% growth in 2024, the company is well-positioned to propel diabetes care innovation globally. Investors and stakeholders can expect exciting developments as Insulet continues to revolutionize healthcare solutions for people with diabetes.
For full details, see the source document from SEC.
Tags: InsuletLeadership, MedTechInnovation, DiabetesCare, CEOTransition, OmnipodTechnology